1:44 PM
 | 
Nov 05, 2018
 |  BC Extra  |  Company News

NextCure, Lilly partner to find new immuno-oncology targets

PD-1 pioneer Lieping Chen's NextCure Inc. (Beltsville, Md.) partnered with Eli Lilly and Co. (NYSE:LLY) to use the biotech's FIND-IO platform to discover immuno-oncology targets.

FIND-IO identifies new targets on immune-suppressive macrophages, dendritic cells and other antigen-presenting cells. Unlike discovery platforms that...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >